Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
34 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
3 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
136 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
GHU APHP NUP SITE LOUIS MOURIER
178 R DES RENOUILLIERS, 92701 COLOMBES CEDEX
MAS PRINCESSE MATHILDE
42 AV DU ROULE, 92200 NEUILLY SUR SEINE
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
IEM DE L ORMAILLE
1 R DE LA FONTAINE ST MATHIEU, 91440 BURES SUR YVETTE
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Clinical pediatrics · 2013
Aim. To assess the current knowledge and evaluate the quality of evidence in the use of FESS for the treatment of chronic rhinosinusitis in children, regarding the respective changes in the quality-of-their-life (QoL) and the outcome that follows the operation. Materials/Methods. Systematic literature review in Medline and other database sources and meta-analysis of pooled data. Results. 15 studies were systematically analyzed. Four represented Level II, five Level III, and six Level IV evidence. The total number of treated patients was 1301. Thirteen research groups reported that pediatric FESS is an effective treatment for chronic rhinosinusitis; the respective positive outcome ranged between 71 and 100% of operated children. Five studies concluded that this treatment modality is associated with significant improvement in the children’s postoperative QoL. Systemic diseases and environmental factors may have unfavourable prognostic effects; cystic fibrosis is associated with at least 50% recurrence rate. The rate of major complications following pediatric FESS is 0.6%, and the respective rate of minor complications 2%. Conclusion. The surgical management in children with chronic rhinosinusitis, despite the reservations expressed by many clinicians, is effective when optimal medical treatment proves unsuccessful (grade B strength of recommendation), and is associated with improvement in the children’s QoL (grade B strength of recommendation). FESS also improves the sinusitis-associated symptoms and QoL in children with cystic fibrosis (grade C strength of recommendation. Most complications of pediatric FESS reported in the literature are minor, and associated with difficulties in the postoperative assessment and care of pediatric patients.
Neurology(R) neuroimmunology & neuroinflammation · 2023
Lupus · 2008
Mycophenolate mofetil (MMF) with prednisolone has been associated with high remission rates when used as induction treatment for lupus nephritis. This prospective, multicentre, cohort study investigates the efficacy and safety of this regimen over 24 weeks in 213 Chinese patients with active lupus nephritis (Classes III, IV, V or combination). Baseline activity index (AI) was 6.91 ± 3.33 and chronicity index (CI) was 1.9 ± 1.2. The remission rate was 82.6% at 24 weeks (complete remission, 34.3%; partial remission, 48.4%). There were significant ( P < 0.01) improvements in kidney function shown by reductions in proteinuria, serum albumin, serum creatinine and creatinine clearance, as well as in systemic lupus erythematosus disease activity index (SLEDAI) scores. Independent risk factors influencing remission were pathological classification (including Class V and III or Class V and IV nephritis) and elevated serum creatinine at baseline (OR 2.967, 95% CI: 1.479–6.332, P = 0.001 and OR 1.007, 95% CI: 1.002–1.011, P = 0.001, respectively). Patients with concomitant membranous features on biopsy had a lower remission rate than those with Class III and IV nephritis (66.7% vs 87.3%, P = 0.002). Renal biopsy was repeated in 25 patients following treatment. There was a transition to less severe pathological morphologies in majority of subjects. Infections were monitored throughout treatment: eight patients (3.8%) experienced bacterial infections, whereas herpes zoster occurred in seven patients. Nine patients (4.2%) suffered from gastrointestinal upset, which resolved without discontinuation of MMF. One patient became leucopenic, whereas another died from active disease unrelated to kidney symptoms. MMF combined with prednisolone is an effective and well-tolerated induction treatment for patients with active lupus nephritis and for controlling SLE systemic activity.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Neurology(R) neuroimmunology & neuroinflammation · 2026 · Journal Article
Fetta A, Conti F, Lopalco A, Corsini C, et al.
Epilepsia · 2025 · Journal Article
Rosati A, Bartolotta P, Marini C, Mondardini MC, et al.
Epilepsia · 2025 · Journal Article
Fetta A, Bergonzini L, Dondi A, Belotti LMB, et al.
The Lancet. Neurology · 2025 · Journal Article
Olivé-Cirera G, Fonseca E, Chen LW, Fetta A, et al.
Neuropediatrics · 2024 · Journal Article
Chiarello D, Perrone A, Ricci E, Ferrera G, et al.
Seizure · 2024 · Journal Article
Bergonzini L, Leardini D, Rao R, Foiadelli T, et al.
Journal of clinical medicine · 2024 · Journal Article
Russo A, Mazzone S, Landolina L, Colucci R, et al.
Orphanet journal of rare diseases · 2024 · Review
Fetta A, Toni F, Pettenuzzo I, Ricci E, et al.
Cells · 2023 · Journal Article
Conti F, Moratti M, Leonardi L, Catelli A, et al.
Frontiers in neurology · 2023 · Journal Article
Perilli L, Fetta M, Capponi M, Guido CA, et al.
European journal of pediatrics · 2023 · Observational Study
Pruccoli J, Biagi C, Andreozzi L, Fetta A, et al.
Children (Basel, Switzerland) · 2023 · Journal Article
Dondi A, Biserni GB, Scarpini S, Fetta A, et al.
Neurology(R) neuroimmunology & neuroinflammation · 2023 · Multicenter Study
Nosadini M, Eyre M, Giacomini T, Valeriani M, et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · 2022 · Journal Article
Orsini A, Foiadelli T, Magistrali M, Carli N, et al.
Frontiers in neurology · 2021 · Journal Article
Fetta A, Di Pisa V, Ruscelli M, Soliani L, et al.
Italian journal of pediatrics · 2021 · Journal Article
Dondi A, Fetta A, Lenzi J, Morigi F, et al.
Brain sciences · 2021 · Journal Article
Fetta A, Carati E, Moneti L, Pignataro V, et al.
International journal of pediatric otorhinolaryngology · 2017 · Journal Article
Fetta M, Tsilis NS, Segas JV, Nikolopoulos TP, et al.
Clinical pediatrics · 2013 · Journal Article
Vlastarakos PV, Fetta M, Segas JV, Maragoudakis P, et al.
Neurobiology of disease · 2026 · Journal Article
Musante I, Gorrieri G, Tamburro S, Ferrera G, et al.
European journal of human genetics : EJHG · 2024 · Journal Article
Caraffi SG, van der Laan L, Rooney K, Trajkova S, et al.
Genes · 2022 · Journal Article
Fetta A, Soliani L, Trevisan A, Pugliano R, et al.
Genes · 2022 · Journal Article
Neurology(R) neuroimmunology & neuroinflammation · 2026 · Journal Article
Gligora I, Businaro P, Serra L, De Pasqua S, et al.
The Lancet. Neurology · 2025 · Journal Article
Olivé-Cirera G, Fonseca E, Chen LW, Fetta A, et al.
Children (Basel, Switzerland) · 2023 · Journal Article
Dondi A, Biserni GB, Scarpini S, Fetta A, et al.
Neurology(R) neuroimmunology & neuroinflammation · 2026 · Journal Article
Fetta A, Conti F, Lopalco A, Corsini C, et al.
Frontiers in neurology · 2023 · Journal Article
Perilli L, Fetta M, Capponi M, Guido CA, et al.
Genes · 2023 · Systematic Review
Bergonzini L, Pruccoli J, Pettenuzzo I, Pugliano R, et al.
Neurology(R) neuroimmunology & neuroinflammation · 2023 · Multicenter Study
Nosadini M, Eyre M, Giacomini T, Valeriani M, et al.
Lupus · 2008 · Clinical Trial
F L, Y T, X P, L W, et al.
International journal of pediatric otorhinolaryngology · 2017 · Journal Article
Fetta M, Tsilis NS, Segas JV, Nikolopoulos TP, et al.
Clinical pediatrics · 2013 · Journal Article
Vlastarakos PV, Fetta M, Segas JV, Maragoudakis P, et al.
Genes · 2023 · Systematic Review
Bergonzini L, Pruccoli J, Pettenuzzo I, Pugliano R, et al.
Clinical pediatrics · 2013 · Journal Article
Vlastarakos PV, Fetta M, Segas JV, Maragoudakis P, et al.
Frontiers in neurology · 2021 · Journal Article
Fetta A, Di Pisa V, Ruscelli M, Soliani L, et al.
Italian journal of pediatrics · 2021 · Journal Article
Dondi A, Fetta A, Lenzi J, Morigi F, et al.
International journal of molecular sciences · 2025 · Case Reports
Baldini L, Del Vecchio L, Cerasi S, Fetta A, et al.
JMIR research protocols · 2024 · Journal Article
Starkweather AR, Xu W, Gnall KE, Emrich M, et al.
BMJ case reports · 2026 · Journal Article
F A, George OK, Alex AG, Sahitya MS
Journal of clinical medicine · 2024 · Journal Article
Russo A, Mazzone S, Landolina L, Colucci R, et al.
Epilepsia · 2025 · Journal Article
Fetta A, Bergonzini L, Dondi A, Belotti LMB, et al.
Orsini A, Santangelo A, Bravin F, Bonuccelli A, et al.
Frontiers in bioscience (Landmark edition) · 2021 · Journal Article
Kontoghiorghes GJ, Fetta S, Kontoghiorghe CN
Epilepsy & behavior : E&B · 2021 · Journal Article
Ricci E, Fetta A, Garavelli L, Caraffi S, et al.
Genes · 2021 · Journal Article
Cordelli DM, Di Pisa V, Fetta A, Garavelli L, et al.
Drug design, development and therapy · 2019 · Journal Article
Kameoka Y, F K, M K
Psychiatry research · 2017 · Journal Article
Martin CG, Kim H, Yun S, Livingston W, et al.